Company Overview

Tempus AI Inc. is a leader in the healthcare AI space, leveraging advanced machine learning models and massive datasets to enable precision medicine. The company serves both clinical providers and pharmaceutical researchers, focusing on oncology, cardiology, radiology, and more. With a successful IPO and rapid product rollouts, Tempus is reshaping the future of diagnostics and drug discovery.

Stock Snapshot

Symbol: TEM (NASDAQ)

Current Price: ~$69.10

IPO Date: June 14, 2024

52-Week Range: $22.89 – $91.45

Market Cap: ~$12B

Recent Change: -1.07 (-1.5%)

Day Range: $66.73 – $71.64

Volume: ~10.7M

Open: $69.05

Institutional Interest: Strong (incl. J.P. Morgan, SoftBank)

Key Developments

June 2024: FDA approved Tempus ECG‑AF, an AI-based atrial fibrillation risk detector.
April 2025: Launched Loop — an AI-driven CRISPR and RWD-based platform for preclinical target discovery.
Q2 2025: Analysts from BofA, JPM, and Stifel issue "Buy" ratings.
Pelosi Surge: +35% jump linked to political investor activity and bullish app launch.
Spruce Point Short: Bearish call with a 50–60% downside warning.

Recent News

Tempus AI Soars 35% After Pelosi Investment Buzz

Published by Investopedia, June 18, 2025

Tempus AI stock surged 35% in a single day after disclosures linked to Nancy Pelosi's investment caused a bullish rally. The spike reflects growing institutional and political interest in AI-driven healthcare companies.

Wall Street Shows Confidence in Tempus AI

Published by Investopedia, June 16, 2025

Major firms including J.P. Morgan and Bank of America issued "Buy" ratings for Tempus AI citing strong growth potential, solid AI integrations, and a robust healthcare market.

FDA Approves Tempus ECG-AF

Published by MarketWatch, June 14, 2024

The U.S. FDA has cleared Tempus AI's ECG-AF, an AI-powered diagnostic tool capable of identifying patients at high risk for atrial fibrillation, strengthening the company’s regulatory credibility.

Deep Dive: Tempus AI Inc. (TEM) Stock Insights

Ticker: TEM (Nasdaq) | Sector: AI-Powered Precision Medicine & Genomics

Price (as of June 20, 2025): ~$69.10 USD

1. Big Data & Major Partnerships

$200M licensing deal with AstraZeneca and Pathos AI for an oncology AI foundation model
Collaborations with Northwestern University and Genialis for genomic and RNA algorithm research

2. Product Innovations

xM Liquid Biopsy: Real-time monitoring for cancer immunotherapy response
Tempus One: AI assistant with 1,000+ clinical workflow automations
Fuses: EHR-integrated AI middleware for diagnostics and trial-matching

3. Financial Overview (Q1 2025)

Revenue: $255.7 million (+75% YoY)
Gross Profit: ~$155 million
Net Loss: $68 million (includes stock-based comp)
Debt-to-Equity Ratio: ~2.45×

4. Legal Risks & Volatility

Class-action lawsuit filed (deadline: Aug 12, 2025) over alleged misrepresentation
Stock dropped ~19% after short-seller report in late May

5. Technicals & Analyst Ratings

RS Rating: Over 90 (strong momentum)
Chart Signal: Rounded bottom pattern with breakout potential
Needham: $70 price target
JPMorgan: $55 price target (Neutral)

6. Strategic Summary

Strengths	Risk Factors
High revenue growth and margins	Still operating at a net loss
Unique AI-genomic dataset	Ongoing legal scrutiny and short interest
Clinical momentum and EHR integration	High leverage and volatility

Final Thoughts

Tempus AI is a front-runner in applying artificial intelligence to healthcare data, making it a key player in the evolution of personalized medicine. With rapid growth, significant partnerships, and a growing product suite, its future is promising—but investors should monitor legal developments, path to profitability, and market volatility closely.

Sources: Barron’s, Investors.com, Tempus IR, GlobeNewswire, Nasdaq

Frequently Asked Questions (FAQs)

What does Tempus AI Inc. specialize in?

Tempus AI focuses on AI-powered precision medicine, combining genomic sequencing, real-world clinical data, and machine learning models to improve diagnostics and treatment decisions in oncology and other specialties.

Is TEM stock considered a high-risk investment?

Yes. While the company is experiencing rapid growth, it is still unprofitable, carries high debt, and has been subject to legal scrutiny. This makes it a high-risk, high-reward investment for growth-focused portfolios.

What are the main revenue drivers for Tempus?

Tempus generates revenue through sequencing services, AI software solutions for clinicians, and data licensing deals with pharmaceutical companies. Key products include the xM assay, Tempus One assistant, and clinical trial matching tools.

Why is there a lawsuit against Tempus AI?

A class-action lawsuit has been filed alleging misrepresentation of certain business metrics and forward-looking statements. The legal proceedings are ongoing, and investors have until August 12, 2025, to join the suit.

How does Tempus differ from other biotech companies?

Unlike many traditional biotech firms, Tempus sits at the intersection of healthcare and big data. It emphasizes machine learning, cloud-scale datasets, and digital infrastructure integrated directly into hospitals and EHRs.

Tempus AI Inc. (NASDAQ: TEM)

Precision Medicine Powered by AI